



# Embryo and Oocyte Banking

*Lynn M. Westphal, Jamie A. M. Massie, and Jessica A. Lentscher*

- 6.1 Introduction – 72**
- 6.2 Candidates for Fertility Preservation – 72**
- 6.3 Embryo Banking – 73**
  - 6.3.1 Procedure – 73
  - 6.3.2 Cost – 73
  - 6.3.3 Timing – 74
  - 6.3.4 Risks – 74
  - 6.3.5 Success Rates – 74
- 6.4 Oocyte Banking – 74**
  - 6.4.1 Procedure – 74
  - 6.4.2 Cost – 75
  - 6.4.3 Timing – 75
  - 6.4.4 Risks – 75
  - 6.4.5 Success Rates – 75
- 6.5 Tumor-Specific Considerations – 76**
  - 6.5.1 Breast Cancer – 76
  - 6.5.2 Ovarian Cancer – 76
  - 6.5.3 Hematologic Malignancies – 76
  - 6.5.4 Endometrial Cancer – 76
  - 6.5.5 Cervical Cancer – 77
- 6.6 Conclusions – 77**
- Review Questions and Answers – 77**
- References – 78**

### Key Points

- Significant improvements in treatments in oncologic conditions have increased survival rates in reproductive-age women, and as a result, a woman's fertility potential is an important counseling area for pre-cancer treatment.
- Embryo cryopreservation before chemotherapy is the most well-established and widely available method of fertility preservation for women; oocyte cryopreservation gives women the most reproductive autonomy.
- Oocyte or embryo banking require controlled ovarian hyperstimulation and oocyte retrieval procedures and take approximately 12–14 days to complete. Patients must carefully consult with their gynecologic oncologist or oncologist prior to determine if this modest delay in treatment will significantly impact their treatment and prognosis.
- The majority of reproductive-age women who are diagnosed with cancer are candidates for fertility preservation and should receive counseling prior to the initiation of cancer treatments.

## 6.1 Introduction

Due to significant improvements in cancer treatments, patients affected by oncologic disease are living longer, fuller lives. As a result, the fertility potential of reproductive-age women affected by cancer has become an increasing focus for those who counsel and treat such patients. Indeed, patients who have undergone fertility preservation procedures prior to oncological treatment report that fertility preservation positively impacted their quality of life during treatment [1].

Advances in reproductive medicine now allow patients diagnosed with cancer during their reproductive years to undergo various fertility preservation techniques, maintaining the potential for childbearing following successful cancer treatment [2–4]. In addition, fertility preservation options, such as oocyte cryopreservation, are now available for those patients with ethical, religious,

or social concerns that may prohibit the creation and storage of embryos.

In this chapter, we will focus on the use of embryo and oocyte banking for fertility preservation.

## 6.2 Candidates for Fertility Preservation

Women of reproductive age who are scheduled to undergo medical treatment that could lead to premature decline of ovarian function should be counseled regarding the possibility of oocyte or embryo cryopreservation [3, 5]. Prior to initiating treatment in a patient who desires fertility preservation, a screening examination should be performed in order to confirm that the patient is a good candidate. A baseline fertility assessment, such as an antral follicle count (AFC) and measurement of anti-Müllerian hormone (AMH) and/or day 3 follicle-stimulating hormone (FSH) levels, should be part of the evaluation. In addition, tumor type and stage, timing and gonadotoxicity of chemotherapy, and overall health of the patient should be taken into consideration before initiating fertility treatment. Information collected in this baseline assessment not only aids the physician in selecting appropriate medication doses but also allows for appropriate counseling regarding expected success rates following the procedure.

The standard procedure for embryo and oocyte cryopreservation requires controlled ovarian hyperstimulation and oocyte retrieval, a process that requires approximately 12–14 days. If chemotherapy cannot be postponed for this period of time without potential compromise to the patient's immediate or long-term treatment outcomes, other fertility preservation options should be explored.

Patients should be counseled regarding all fertility preservation methods that are applicable to their specific circumstance [6, 7]. Ideally, this counseling should be performed by a physician specializing in reproductive endocrinology and infertility who has experience working with cancer patients. During the counseling session, potential complications of these treatments, such as ovarian hyperstimulation syndrome and intra-abdominal bleeding, should be discussed in detail. Although the incidence of such complications is

low, occurring in approximately 5% of cycles, the potential impact of these complications on the patient's current health status and/or plans to move forward with cancer treatment may be significant [8, 9].

### 6.3 Embryo Banking

Since the first reported birth in 1983, several hundred thousand children have been born from cryopreserved embryos created during in vitro fertilization (IVF) cycles. For women with a committed male partner, or who are prepared to use donor sperm, embryo cryopreservation before chemotherapy is the most well-established and widely available method of fertility preservation [10–12]. This technique involves the collection of oocytes followed by fertilization in the laboratory and subsequent freezing of viable embryos.

#### 6.3.1 Procedure

The embryo banking procedure begins with controlled ovarian hyperstimulation with injectable gonadotropins. The stimulation has traditionally started the second or third day of full menstrual flow; however, success can be achieved with initiation of ovarian stimulation during any phase of the menstrual cycle [13–15].

A classic GnRH antagonist protocol is most often employed as it can be completed quickly and has been associated with a lower risk of ovarian hyperstimulation syndrome [16]. A typical cycle is as follows:

- Daily injections with gonadotropins begin on cycle day 2 or 3 and continue daily for an average of 10–12 days.
- GnRH antagonist is added to the medication schedule when the largest ovarian follicle measures 14 mm on transvaginal ultrasound.
- Ovulation is triggered with a single injection of human chorionic gonadotropin (hCG).
- Oocyte retrieval is performed 34–36 h following hCG injection.
- Retrieved oocytes are fertilized in the laboratory. Intracytoplasmic sperm injection (ICSI) is recommended when sperm parameters are abnormal and may be chosen even when semen analysis is normal in order to reduce the risk of fertilization failure [17].

- Successful fertilization is assessed on the day following oocyte retrieval, and the embryos are monitored in the laboratory until the time of cryopreservation.
- Embryos may be cryopreserved at the 2PN (i.e., prezygote), day 3 (i.e., 8 cell), or day 5 (i.e., blastocyst) stage. The timing of cryopreservation should be individualized and based upon the wishes of the patient and the recommendation of the treating physician.

When beginning stimulation later in the cycle, a modified GnRH antagonist protocol can be utilized, as follows [5, 13–15]:

- GnRH antagonist is administered as a single 3-mg dose or daily (0.25-mg dose) for 2–3 days to induce menses within 5–7 days, at which time ovarian stimulation can begin [5].
- Alternatively, gonadotropins and GnRH antagonist can be started at the same time and continued throughout the cycle, or antagonist can be added when the leading follicle reaches 13–14 mm.
- Ovulation triggering, fertilization, and embryo cryopreservation are carried out in the same fashion as with the traditional GnRH antagonist protocol.

Ovulation induction with leuprolide acetate (single 0.4-mL (2-mg) injection) can be administered in lieu of the traditional hCG ovulation trigger to reduce the risk of ovarian hyperstimulation syndrome in those patients at risk [18].

#### 6.3.2 Cost

The average cost of an embryo cryopreservation (i.e., IVF) cycle ranges from \$9286 to \$12,513 [19, 20]. In addition, the initial cost of freezing and storage may add several hundred dollars to the total charge, and there will be additional fees at the time the embryos are thawed and transferred. Costs vary from one center to another, and specifics regarding cost should be addressed with the treating physician. Insurance coverage of fertility-preserving treatments is also widely variable, and questions regarding fertility benefits should be directed toward the patient's insurance provider.

There are some nonprofit organizations dedicated to providing support for patients whose medical treatments present the risk of infertility. These organizations, such as Fertile Hope®, a national LIVESTRONG initiative, and the Fertile Action Program, may be able to assist patients with the financial burden associated with undergoing fertility preservation procedures. Information about these organizations may be found online or provided by the treating physician.

### 6.3.3 Timing

The duration of treatment, from stimulation start to oocyte retrieval, is approximately 12–14 days. Chemotherapy can be started 1–2 days after oocyte retrieval. In one study, the effect of beginning chemotherapy before complete recovery of the ovaries after stimulation did not show any increase in ovarian damage [21].

### 6.3.4 Risks

Ovarian stimulation with oocyte retrieval is a relatively low-risk process. However, a small proportion of patients will experience complications such as mild-to-severe ovarian hyperstimulation syndrome or intra-abdominal bleeding. In addition, patients may experience a delay in the initiation of cancer treatment and may have an increased risk of thromboembolic events and theoretic stimulation of estrogen-sensitive cancers [22]. In the long term, the procedure may fail to produce retrievable eggs, produce embryos, or result in a pregnancy or live birth.

### 6.3.5 Success Rates

Published data suggest that women opting for embryo cryopreservation prior to initiation of cancer treatment can expect success rates similar to those of women undergoing IVF for male factor infertility [23, 24]. Parameters to define success, such as oocyte yield, number of embryos cryopreserved, pregnancy rates, and live birth rates, are highly dependent upon the patient's age and baseline fertility evaluation. **Table 6.1** shows national success rates for thawed embryo cycles by age.

**Table 6.1** Thawed embryo success rates

Age (years)	<35	35–37	38–40	41–42
Number of thaw procedures	14,756	7733	5342	1693
Live birth/egg retrieval cycle	42.5%	39.5%	33.5%	27.8%

Data from 2014 SART statistics (Final Subsequent Outcome (Frozen Cycles), filtered for “frozen embryo”) SART Society for Assisted Reproductive Technology

## 6.4 Oocyte Banking

Advances in oocyte cryopreservation have allowed more women to pursue fertility preservation. Because a sperm source is not needed before oocyte cryopreservation, women without a male partner may consider this option. In addition, oocyte cryopreservation presents those patients who have ethical or religious objections to the creation of embryos for storage with an alternative treatment choice. This option gives women the most reproductive autonomy and should be offered to all women.

When first introduced in the 1980s, the ability of a cryopreserved oocyte to be fertilized and result in a live birth was compromised by poor oocyte survival and poor fertilization rates [25–29]. However, improvements in cryopreservation techniques have resulted in significantly improved outcomes in patients opting for this method [30–32]. In 2013, the American Society for Reproductive Medicine (ASRM) and the Society for Assisted Reproductive Technology (SART) published a joint document which cited the improvements in pregnancy success using cryopreserved oocytes and stated that oocyte cryopreservation should no longer be considered experimental [33]. Further, ASRM recommends that patients facing infertility due to treatment with gonadotoxic therapies undergo oocyte cryopreservation with appropriate counseling.

### 6.4.1 Procedure

The oocyte banking procedure follows the same ovarian stimulation protocols as outlined above for embryo banking. As in the case of embryo

cryopreservation, the stimulation start date is traditionally the 2nd or 3rd day of full menstrual flow but can be performed at any time during the menstrual cycle [13–15].

Following oocyte retrieval, oocytes are prepared for cryopreservation. Two methods of oocyte cryopreservation are available: slow freezing and vitrification [34]. With the slow-freezing method, the oocyte is placed in a low concentration of cryoprotective solution that acts as “antifreeze” by disrupting hydrogen bonds between water, and the oocyte is then slowly frozen in a programmable freezer. In vitrification, the oocyte is placed in a high concentration of cryoprotective agents and then rapidly cooled using liquid nitrogen. The thawing process is also ultrarapid in order to avoid ice nucleation.

Current evidence suggests that vitrification results in higher survival, fertilization, implantation, and pregnancy rates than slow freezing [29, 35, 36]. Therefore, the vitrification technique is the preferred method for oocyte cryopreservation, although a number of pregnancies have been reported using oocytes that were cryopreserved using the slow-freezing method [34, 35, 37, 38].

### 6.4.2 Cost

The average cost of an oocyte cryopreservation cycle is approximately \$7791 [19]. In addition, the initial cost of freezing and storage may add several hundred dollars to the total charge, and there are additional fees at the time of thawing and transfer. Costs vary from center to center, and specifics should be addressed by the treating physician. As with embryo cryopreservation, insurance coverage is widely variable and questions regarding fertility benefits should be directed toward the patient’s insurance provider. Patients may also look into financial assistance programs for cancer survivors as described earlier.

### 6.4.3 Timing

The duration of treatment, from stimulation start to oocyte retrieval, is approximately 12–14 days. Chemotherapy can be started 1–2 days after oocyte retrieval. In one study, the effect of begin-

ning chemotherapy before complete recovery of the ovaries after stimulation showed no increase in ovarian damage [21].

### 6.4.4 Risks

Medical risks are similar to that for embryo cryopreservation. In addition, there is a risk that the oocytes may not survive thawing, not fertilize, or not result in a pregnancy in the future. Although short-term data are reassuring with regard to the incidence of chromosomal abnormalities and congenital anomalies in pregnancies achieved with cryopreserved oocytes, long-term data on developmental outcomes are lacking [33, 39].

### 6.4.5 Success Rates

There is compelling evidence that pregnancy rates in patients using cryopreserved oocytes are similar to those achieved with IVF utilizing fresh oocytes in young patients [33, 40, 41]. ■ Table 6.2 shows national success rates for thawed oocyte cycles by age.

The success of an oocyte cryopreservation cycle (i.e., oocyte yield) is highly dependent upon the patients’ age and baseline fertility evaluation. It is important to provide individualized counseling, taking into account the above factors as well as clinic-specific success rates, when discussing likelihood of live birth following oocyte cryopreservation [33].

■ Table 6.2 Thawed oocyte success rates

Age (years)	<35	35–37	38–40	41–42
Number of thaw procedures	109	52	47	61
Live birth/egg retrieval cycle	34.9%	25.0%	17.0%	19.7%

Data from 2014 SART statistics (Final Subsequent Outcome (Frozen Cycles), filtered for “frozen embryo”) SART Society for Assisted Reproductive Technology

## 6.5 Tumor-Specific Considerations

### 6.5.1 Breast Cancer

Breast cancer is the most common neoplasm diagnosed during the reproductive years, with more than 15% of all new breast cancer diagnoses occurring under the age of 40 years [42–44]. The treatment of invasive breast cancer often includes gonadotoxic agents. As a result, a significant proportion of cancer survivors suffer from premature ovarian insufficiency, making this population an important target for fertility preservation counseling and treatment.

Historically, women with breast cancer have not been offered embryo or oocyte cryopreservation to preserve fertility due to the theoretical risk of tumor progression with the high estradiol levels that often occur during ovarian stimulation. However, standard stimulation protocols can be modified to include the selective estrogen modulator tamoxifen or the aromatase inhibitor letrozole. In one protocol, letrozole (5 mg/day) can be administered at the same time as gonadotropins and continued for 7 days after oocyte retrieval. The addition of an aromatase inhibitor allows for ovarian stimulation without significant increases in estradiol levels [45]. As a result, breast cancer patients should be offered the option of embryo or oocyte cryopreservation.

The timing of ovarian stimulation is of particular importance in patients with invasive breast cancer. In general, the initiation of ovarian stimulation is preferred after surgical excision, especially in those patients with hormone receptor-positive tumors. Instead, ovarian stimulation is best started in the hiatus between surgical excision and chemotherapy. In most cases, surgical excision precedes the initiation of chemotherapy by 4–6 weeks, allowing for sufficient time to undergo ovarian stimulation for fertility preservation. Retrospective studies have shown no significant delay in breast cancer treatment in patients who decide to undergo ovarian stimulation [46, 47]. Furthermore, ovarian stimulation in patients with both hormone receptor-positive and hormone receptor-negative tumors has not been associated with any difference in disease-free survival and overall survival rates compared with those not undergoing fertility preservation procedures [48, 49].

### 6.5.2 Ovarian Cancer

In the past, the options for fertility preservation in patients with ovarian cancer were severely limited due to the extensive surgical management that treatment of such malignancies involved. The standard of care for ovarian cancer treatment in most cases included total abdominal hysterectomy, bilateral salpingo-oophorectomy, and comprehensive surgical staging. However, less radical surgical management, such as unilateral salpingo-oophorectomy, can be considered in carefully selected cases [50]. Studies examining the 5-year survival rate of patients with early-stage disease showed no difference in survival between those who underwent fertility-sparing procedures and those who did not [51]. Generally speaking, women with early-stage ovarian cancer may be candidates for fertility preservation via embryo or oocyte cryopreservation.

### 6.5.3 Hematologic Malignancies

The treatment of hematologic malignancies is frequently associated with significant gonadal toxicity, making fertility preservation counseling and treatment of utmost importance in this population [52, 53]. Complicating the treatment of such patients is the urgency to begin cancer therapy as early as possible after diagnosis. Patients due to undergo immediate cancer treatment are not candidates for embryo or oocyte cryopreservation and should, instead, be offered alternative methods of fertility preservation. For those patients in whom a 2-week treatment delay is acceptable, one can proceed with embryo and/or oocyte cryopreservation using the routine protocol. As patients usually begin chemotherapy shortly after oocyte retrieval, the use of leuprolide acetate for ovulation induction can speed the interval from oocyte retrieval to next menses and minimize the symptoms of ovarian stimulation.

### 6.5.4 Endometrial Cancer

In reproductive-age women, endometrial cancer tends to be associated with prolonged unopposed estrogen exposure. This may be the result of obesity, anovulation, and/or polycystic ovary syndrome. As these conditions are often associated with infertility,



approximately 15% of young patients found to have endometrial cancer are actually identified during the course of infertility workup [54].

Traditionally, the treatment for endometrial cancer has included total hysterectomy and bilateral salpingo-oophorectomy. Alternative treatments that may allow for fertility conservation are available for patients who meet certain criteria. Women with low-grade endometrial cancer may choose to treat their disease with hormonal therapy rather than surgery. In these cases, oral progestational agents may be used in an attempt to convert the endometrium back to a benign state [55–58]. Conservative surgical management with ovarian preservation may also be an option for those patients who are considering the use of a gestational carrier for child-bearing.

In those patients who are not felt to be candidates for conservative therapy, ovarian stimulation with embryo and/or oocyte cryopreservation followed by definitive surgical treatment may be employed. A progestin-containing IUD can be placed during the stimulation [58]. It should be noted that there is a significant risk of disease recurrence and/or progression when conservative treatments for endometrial cancer are employed [59]. The decision to proceed with these types of therapy should be done only with the recommendation and guidance of a trained gynecologic oncologist.

### 6.5.5 Cervical Cancer

Cervical cancer is most commonly diagnosed during the reproductive years and frequently affects women who have not completed child-bearing. Conventional treatment for cervical cancer may include radical hysterectomy with or without postoperative pelvic radiation and chemotherapy; however, women with early-stage disease (1A2 and 1B1) may be candidates for more conservative surgical therapy. Radical trachelectomy (surgical removal of the uterine cervix) in carefully selected patients allows for fertility preservation without a significant difference in survival rates compared with those undergoing radical hysterectomy [60, 61].

In patients undergoing hysterectomy, ovarian stimulation can be performed either pre- or postoperatively. When embryo and/or oocyte

cryopreservation is pursued postoperatively, the starting point for stimulation can be made serologically, as menses cannot be used as the starting point, or a random start can be used. In addition, if oophorectomy is performed at the time of hysterectomy, ovarian monitoring and retrieval may need to be done transabdominally. Furthermore, manipulation of the ovaries may affect blood supply and decrease responsiveness to stimulation.

## 6.6 Conclusions

As earlier detection and treatment allow cancer patients to live longer, fuller lives, the need for timely and comprehensive counseling regarding fertility preservation in these women has become an important quality of life issue. Fortunately, the majority of reproductive-age women who are diagnosed with cancer are candidates for fertility preservation, often by embryo and/or oocyte cryopreservation. All women should be made aware of their options for fertility preservation, allowing them the potential to fulfill their reproductive goals.

**Acknowledgment** This work was supported by the Oncofertility Consortium NIH/NICHD 5UL1DE019587.

## Review Questions and Answers

- ❓ Q1. What evaluation is included prior to initiation of oocyte/embryo preservation?
- ✔ A1. An antral follicle count, anti-Mullerian hormone level, and/or day 3 FSH level.
- ❓ Q2. Which freezing method results in higher survival, fertilization, implantation, and pregnancy rates?
- ✔ A2. Vitrification is the preferred method for oocyte or embryo preservation.
- ❓ Q3. In carefully selected patients with early-stage ovarian cancer, does fertility-sparing treatment change survival rate?

- ✓ A3. Studies have not shown a difference in 5-year survival rates between those who underwent fertility-sparing procedures and those who did not.
- ? Q4. In an effort to decrease estrogen levels in a controlled ovarian stimulation cycle in patients with hormone-sensitive breast cancer, what modifications can be made to allow patients to proceed with fertility preservation?
- ✓ A4. The addition of an aromatase inhibitor such as letrozole allows for ovarian stimulation without significant increase in serum estradiol levels.

## References

1. Assi J, Santos J, Bonetti T, Serafini PC, Motta ELA, Chihin MB. Psychosocial benefits of fertility preservation for young cancer patients. *J Assist Reprod Genet.* 2018;35(4):601–6. [Epub ahead of print].
2. Lee SJ, American Society of Clinical Oncology, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. *J Clin Oncol.* 2006;24:2917–31.
3. von Wolff M, et al. Fertility preservation in women—a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. *Arch Gynecol Obstet.* 2011;284:427–35.
4. Wright J, et al. Fertility preservation in young women with epithelial ovarian cancer. *Cancer.* 2009;115:4118–26.
5. Noyes N, et al. Oocyte cryopreservation as a fertility preservation measure for cancer patients. *Reprod Biomed Online.* 2011;23:323–33.
6. Kesic V, et al. Fertility preserving management in gynecologic cancer patients: the need for centralization. *Int J Gynecol Cancer.* 2010;20:1613–9.
7. Patel A, et al. Reproductive health assessment for women with cancer: a pilot study. *Reproductive health assessment for women with cancer: a pilot study.* *Am J Obstet Gynecol.* 2009;201:191.e1–4.
8. Forman RG, et al. Severe ovarian hyperstimulation syndrome using agonists of gonadotrophin releasing hormone for in vitro fertilization: a European series and a proposal for prevention. *Fertil Steril.* 1990;53:502–9.
9. MacDougall MJ, Tan SL, Jacobs HS. In vitro fertilization and the ovarian hyperstimulation syndrome. *Hum Reprod.* 1992;7:579–600.
10. Diedrich K, Fauser BC, Devroey P, Evian Annual Reproduction (EVAR) Workshop Group 2009. Cancer and fertility: strategies to preserve fertility. *Reprod Biomed Online.* 2011;22:232–48.
11. Maltaris T, et al. The effect of cancer treatment on female fertility and strategies for preserving fertility. *Eur J Obstet Gynecol Reprod Biol.* 2007;130:148–55.
12. Roberts JE, Oktay K. Fertility preservation: a comprehensive approach to the young woman with cancer. *J Natl Cancer Inst Monogr.* 2005;34:57–9.
13. von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. *Fertil Steril.* 2009;92:1360–5.
14. Ozkaya E, San Roman G, Oktay K. Luteal phase GnRHa trigger in random start fertility preservation cycles. *J Assist Reprod Genet.* 2012;29:503–5.
15. Cakmak H, Rosen M. Random-start ovarian stimulation in patient with cancer. *Curr Opin Obstet Gynecol.* 2015;27:215–21.
16. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. *Reprod Biomed Online.* 2007;14:640–9.
17. Mahutte NG, Arici A. Failed fertilization: is it predictable? *Curr Opin Obstet Gynecol.* 2003;15:211–8.
18. Bodri D, et al. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. *Fertil Steril.* 2009;91:365–71.
19. Beck LN. The average cost of fertility preservation for female cancer patients. Poster presented at 66th annual meeting of the American Society for Reproductive Medicine (ASRM), Denver. 2010.
20. Chambers GM, et al. The economic impact of assisted reproductive technology: a review of selected developed countries. *Fertil Steril.* 2009;91:2281–94.
21. Maman E, et al. Does controlled ovarian stimulation prior to chemotherapy increase primordial follicle loss and diminish ovarian reserve? An animal study. *Hum Reprod.* 2009;24:206–10.
22. The Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. *Fertil Steril.* 2013;100:1214–23.
23. Robertson AD, Missmer SA, Ginsburg ES. Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy. *Fertil Steril.* 2011;95:588–91.
24. Knopman JM, et al. Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. *Fertil Steril.* 2009;91:1476–8.
25. Chen C. Pregnancy after human oocyte cryopreservation. *Lancet.* 1986;1:884–6.
26. Sonmezer M, Oktay K. Fertility preservation in female patients. *Hum Reprod Update.* 2004;10:251–66.
27. Porcu E. Oocyte freezing. *Semin Reprod Med.* 2001;19:221–30.
28. Van der Elst J. Oocyte freezing: here to stay? *Hum Reprod Update.* 2003;9:463–70.
29. Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. *Fertil Steril.* 2006;86:70–80.



30. Grifo JA, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. *Fertil Steril.* 2010;93:391–6.
31. Barritt J, et al. Report of four donor-recipient oocyte cryopreservation cycles resulting in high pregnancy and implantation rates. *Fertil Steril.* 2007;87:189.e13–7.
32. Cobo A, et al. Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method. *Fertil Steril.* 2008;89:1657–64.
33. Practice Committees of American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. *Fertil Steril.* 2013;99:37–43.
34. Fadini R, et al. Human oocyte cryopreservation: comparison between slow and ultrarapid methods. *Reprod Biomed Online.* 2009;19:171–80.
35. Smith GD, et al. Prospective randomized comparison of human oocyte cryopreservation with slow-rate freezing or vitrification. *Fertil Steril.* 2010;94:2088–95.
36. Gook DA, Edgar DH. Human oocyte cryopreservation. *Hum Reprod Updat.* 2007;13:591–605.
37. Cao YX, et al. Comparison of survival and embryonic development in human oocytes cryopreserved by slow-freezing and vitrification. *Fertil Steril.* 2009;92:1306–11.
38. Martínez-Burgos M, et al. Vitrification versus slow freezing of oocytes: effects on morphologic appearance, meiotic spindle configuration, and DNA damage. *Fertil Steril.* 2011;95:374–7.
39. Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. *Reprod Biomed Online.* 2009;18:769–76.
40. Cobo A, et al. Use of cryo-banked oocytes in an ovum donation programme: a prospective, randomized, controlled, clinical trial. *Hum Reprod.* 2010;25:2239–46.
41. Nagy ZP, et al. Clinical evaluation of the efficiency of an oocyte donation program using egg cryo-banking. *Fertil Steril.* 2009;92:520–6.
42. Hankey BF, et al. Trends in breast cancer in younger women in contrast to older women. *J Natl Cancer Inst Monogr.* 1994;16:7–14.
43. Higgins S, Haffty BG. Pregnancy and lactation after breast-conserving therapy for early stage breast cancer. *Cancer.* 1994;73:2175–80.
44. Goodwin PJ, et al. Risk of menopause during the first year after breast cancer diagnosis. *J Clin Oncol.* 1999;17:2365–70.
45. Oktay K, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. *J Clin Endocrinol Metab.* 2006;91:3885–90.
46. Baynosa J, et al. Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation. *J Am Coll Surg.* 2009;5:603–7.
47. Madrigano A, Westphal L, Wapnir I. Egg retrieval with cryopreservation does not delay breast cancer treatment. *Am J Surg.* 2007;194:477–81.
48. Azim A, Constantini-Ferando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. *J Clin Oncol.* 2008;26:2630–5.
49. Hashimoto T, Nakamura Y, Obata R, Doshida M, Toya M, Takeuchi T, Kyono K. Effects of fertility preservation in patients with breast cancer: a retrospective two-centers study. *Reprod Med Biol.* 2017;16(4):374–9.
50. Morice P, et al. Recommendations of the fertility task force of the European society of gynecologic oncology about the conservative management of ovarian malignant tumors. *Int J Gynecol Cancer.* 2011;21:951–63.
51. Wright JD, et al. Fertility preservation in young women with epithelial ovarian cancer. *Cancer.* 2009;115:4118–26.
52. Grigg AP, et al. Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). *Bone Marrow Transplant.* 2000;26:1089–95.
53. Meirov D, et al. Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients. *Hum Reprod.* 2008;23:1007–13.
54. Kempson R, Pokorny G. Adenocarcinoma of the endometrium in women aged forty and younger. *Cancer.* 1968;21:650–62.
55. Ramirez PT, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. *Gynecol Oncol.* 2004;95:133–8.
56. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. *Obstet Gynecol.* 1997;90:434–40.
57. Yang YC, et al. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. *Gynecol Oncol.* 2005;99:287–93.
58. Juretzka MM, et al. Embryo cryopreservation after diagnosis of stage IIB endometrial cancer and subsequent pregnancy in a gestational carrier. *Fertil Steril.* 2005;83:1041.
59. Chiya L, et al. Sparing fertility in young patients with endometrial cancer. *Gynecol Oncol.* 2008;111:S101–4.
60. Diaz JP, et al. Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. *Gynecol Oncol.* 2008;111:255–60.
61. Plante M, et al. Vaginal radical trachelectomy: an oncologically safe fertility-preserving surgery. An updated series of 72 cases and review of the literature. *Gynecol Oncol.* 2004;94:614–23.